Aurobindo Pharma share news and announcements
NSE: AUROPHARMABSE: 524804Pharmaceuticals & BiotechnologyMid Cap
Last close ₹1,571.70down ₹39.20 (2.43%)BSE ₹1,569.30
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,610.90.
52-week range of traded prices to 23 Oct 2026
₹1,080.10Low, 24 Oct 2025₹1,740.00High, 24 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹90,432 Cr138th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- 24.4
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- 2.4
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 10.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.20
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 6,50,60251.3% delivered
Aurobindo Pharma board and management
40 filed, newest first.
May 2026
Feb 2026
9 Feb · Management
Nov 2025
4 Nov · Management
Oct 2025
Feb 2025
Dec 2024
May 2024
25 May · Management
Apr 2024
7 Apr · Management
Mar 2024
27 Mar · Management
5 Mar · Management
Feb 2024
10 Feb · Management
10 Feb · Management
Nov 2023
9 Nov · Management
Feb 2023
9 Feb · Management
Dec 2022
May 2022
Dec 2021
31 Dec · Management
Oct 2021
May 2021
31 May · Management
Mar 2021
Nov 2020
5 Nov · Management
Mar 2019
30 Mar · Management
Feb 2019
7 Feb · Management
Dec 2017
16 Dec · Management
Sep 2017
1 Sep · Management
Feb 2017
9 Feb · Management
May 2016
Jul 2015
Mar 2015
Feb 2015
5 Feb · Management
Dr.C.Channa Reddy an Independent Director of the Company vide letter dated January 27, 2015 has submitted his resignation due to personal reasons. The Board of Directors of the Company at the meeting held on February 04, 2015 has noted and taken on record the resignation of Dr.C.Channa Reddy as an Independent Director of the Company.
Jul 2014
Nov 2012
9 Nov · Management
Mr.Ravindra Y Shenoy, Joint Managing Director of the Company has tendered his resignation due to his unavoidable personal family reasons. The Board of Directors of the Company at their meeting held on November 09, 2012 have accepted his resignation and consented to relieve Mr.Shenoy of his duties and responsibilities vested by the Board as Director & Joint Managing Director of the Company, with effect from the close of working hours on November 09, 2012
Aug 2012
10 Aug · Management
Dr. P.L. Sanjeev Reddy a Non-Executive and Independent Director ceased to be Director of the Company consequent to his non seeking reappointment at the Annual General Meeting of the Company held on August 07, 2012.
Jan 2012
May 2011
9 May · Management
Board of Directors of the Company at the meeting held on May 09, 2011 has taken on record the resignation of Dr.K.Ramachandran as a Director of the Company.
Oct 2009
30 Oct · Management
Dr. D. Rajagopala Reddy has been appointed as an Additional Director of the Company at the Boar Meeting held on October 30, 2009. He will function as a Non Executive and Independent Director of the Company. Dr. S. Bimal Singh a Non Executive and Independent Director of the Company has resigned from the Board of the Company w.e.f. October 30, 2009.
Jan 2008
30 Jan · Management
Mr. K. Ragunathan, has been appointed as an Additional Director of the Company at the Board Meeting held on 30th January 2008. He will function as a Non Executive and Independent Director of the Company.
Nov 2007
6 Nov · Management
The resignation of Mr. Srinivas Lanka, Non Executive and Independent Director of the Company was taken on record by the Board at its meeting held on 31st October, 2007.
Aug 2007
9 Aug · Management
We deeply regret to advise you of the demise of Dr. K. A. Balasubramanian one of the Independent Directors of the Company on 3rd August 2007. Consequently the present strength of the Board has become nine with four Wholetime Directors and five Non-Executive & Independent Directors